Biotech Exit: Million Arcellx Sparks Investor Reassessment
A notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
Knowing when to rebalance keeps your retirement plan on track. This intro covers indicators and a simple action plan.
17,694 articlesA notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
Kick back this weekend with 10 thoughtful weekend reads that bridge big ideas and real-world investing. Each piece of...
AI growth is fueling demand for data infrastructure, but investors still want reliable income. This article explains ...
In 2026, investors face a critical choice between a clinical-stage biotech and a cash-flow powerhouse. This guide com...
Nvidia investors should watch TSMC's latest results closely. When the world’s largest chipmaker signals stronger dema...
Ark Invest’s latest stance on quantum computing raises questions for Rigetti Computing. This guide breaks down the im...
Dogecoin has volatile history and meme-driven momentum. Here are three grounded reasons I won’t be buying in 2026, pl...
A new Belden stake filed with the SEC shows an investment firm buying $89.5 million worth of shares. This article bre...
Warren Buffett’s moves hint at a bold AI bet. This guide breaks down what makes a killer AI stock and how everyday in...
A flood of political spending from crypto firms aimed at shaping new laws has investors eyeing policy risk. This guid...
A rising institutional move shines a light on how large managers deploy capital in broad market ETFs. This piece brea...
Prediction markets grabbed headlines, but the real long-term payoff in tech comes from AI stocks. This guide explains...